Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure
Source: View publication →
In patients with advanced heart failure and prolonged QRS duration, cardiac resynchronization therapy (CRT) with or without an implantable cardioverter-defibrillator (ICD) added to optimal pharmacologic therapy significantly reduces the risk of the combined endpoint of all-cause mortality or hospitalization.
Key Findings
Study Design
Study Limitations
Clinical Significance
The COMPANION trial established cardiac resynchronization therapy as a cornerstone of management for patients with advanced heart failure, wide QRS complexes, and reduced ejection fraction. It demonstrated that adding biventricular pacing to optimal medical therapy reduces morbidity and mortality, providing a landmark evidence base for the use of CRT and CRT-D devices in clinical practice.
Historical Context
At the time of the COMPANION trial, pharmacological therapy for heart failure had matured, yet mortality remained high. While previous trials like MIRACLE and MUSTIC established that CRT improved functional status and exercise capacity, COMPANION was the first large-scale randomized trial to demonstrate that these devices could improve the hard clinical endpoints of mortality and hospitalizations in a population with advanced disease.
Guided Discussion
High-yield insights from every perspective
What is the physiological basis for using biventricular pacing (CRT) to treat patients with heart failure and a wide QRS complex, and how does it improve cardiac output?
Key Response
In patients with a wide QRS (typically >120ms), there is often ventricular dyssynchrony where the septum and lateral wall do not contract simultaneously. This leads to inefficient mechanical work and reduced stroke volume. CRT uses a third lead (placed via the coronary sinus to the left ventricular epicardium) to pace both ventricles synchronously, restoring a more coordinated contraction, reducing mitral regurgitation, and promoting reverse remodeling of the left ventricle.
The COMPANION trial demonstrated that both CRT-P (pacemaker) and CRT-D (defibrillator) reduced the primary composite endpoint. When managing a patient with NYHA Class III symptoms and a wide QRS, how do you decide between a CRT-P and a CRT-D device based on this evidence?
Key Response
While both devices reduced the risk of death or hospitalization, only the CRT-D group showed a statistically significant reduction in all-cause mortality (36% reduction) in the primary analysis, whereas CRT-P showed a non-significant trend (24% reduction). Residents must balance this survival benefit against the patient's age, comorbidities, and goals of care, as CRT-P may be preferred in patients where ICD shocks are not desired or in those with significant non-cardiac frailty.
Evaluate the incremental benefit of the ICD component in the COMPANION trial. Why did CRT-D show a survival benefit while CRT-P's benefit on mortality alone was less certain, and how does this relate to the mode of death in NYHA Class III vs. IV patients?
Key Response
The ICD component specifically targets sudden cardiac death (SCD). In NYHA Class III patients (the majority of COMPANION), SCD remains a major contributor to mortality. In contrast, in Class IV patients, death is more frequently due to progressive pump failure. COMPANION suggested that while resynchronization improves symptoms and reduces hospitalization across both groups, the ICD provides a critical safety net against tachyarrhythmias that CRT-P alone cannot address.
The COMPANION trial defined 'optimal' medical therapy based on the standards of the early 2000s (ACE inhibitors, beta-blockers, and spironolactone). In the era of modern 'quadruple therapy' (including ARNI and SGLT2i), does the magnitude of benefit from CRT observed in COMPANION remain clinically relevant, or has medical therapy closed the gap?
Key Response
This is a key teaching point: despite the advancement of pharmacotherapy, the mechanical problem of dyssynchrony is not corrected by drugs. While modern GDMT reduces the 'denominator' of risk, CRT remains a class IA recommendation because its mechanism of action—mechanical resynchronization—is additive and independent of neurohormonal blockade. Attending-level insight recognizes that even with ARNI/SGLT2i, patients with wide LBBB still derive significant reverse-remodeling benefit from CRT.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
COMPANION utilized a composite primary endpoint of all-cause mortality or first all-cause hospitalization. Discuss the impact of using 'all-cause' vs. 'cardiovascular-specific' events on the statistical power and the potential for 'noise' within the data.
Key Response
Using all-cause endpoints captures the total burden of disease and avoids the subjectivity/bias of adjudication committees. However, it can dilute the treatment effect if many hospitalizations are for non-cardiac reasons (noise). For CRT research, all-cause hospitalization is a high-frequency event that significantly increases statistical power and reflects the real-world healthcare utilization benefit, though it requires a larger sample size to overcome the non-specific variation compared to CV-specific endpoints.
The COMPANION trial was terminated early by the Data and Safety Monitoring Board (DSMB) after a planned interim analysis. As an editor, what are your concerns regarding the reported Hazard Ratios (HR) for the secondary endpoint of all-cause mortality in the CRT-P group?
Key Response
Early termination for benefit often leads to an overestimation of the treatment effect (the 'Winner's Curse'). While the primary composite endpoint reached high significance, the secondary endpoint of mortality for CRT-P was $p=0.059$. Editors would flag that stopping early may have prevented the CRT-P group from reaching statistical significance for mortality, leaving a degree of uncertainty regarding the relative mortality benefit of CRT-P versus CRT-D that subsequent meta-analyses had to address.
How did the COMPANION results influence the Class of Recommendation for CRT in symptomatic HF patients with QRS >120ms, and how do current guidelines (e.g., 2022 AHA/ACC/HFSA) differentiate the level of evidence for CRT-D versus CRT-P?
Key Response
COMPANION provided the foundational evidence for a Class I recommendation for CRT in NYHA Class III/IV patients with LBBB and QRS duration ≥150ms. Current guidelines prioritize CRT-D (Level of Evidence: A) for patients with a meaningful survival expectation (>1 year) because of the clear mortality benefit shown in COMPANION and RAFT. CRT-P is recommended (Class I) primarily for patients who do not want an ICD or where the primary goal is symptomatic improvement and reduction in HF hospitalizations (Level of Evidence: B-R).
Clinical Landscape
Noteworthy Related Trials
MUSTIC Trial
Tested
Ventricular pacing for cardiac resynchronization
Population
Patients with severe heart failure and intraventricular conduction delay
Comparator
Back-up pacing (no CRT effect)
Endpoint
Exercise capacity and quality of life
MIRACLE Trial
Tested
Cardiac resynchronization therapy
Population
NYHA class III or IV heart failure with wide QRS complex
Comparator
Optimal pharmacological therapy without pacing
Endpoint
Composite of mortality, hospitalization, or functional status improvement
CARE-HF Trial
Tested
Cardiac resynchronization therapy plus medical therapy
Population
NYHA class III or IV heart failure with LV systolic dysfunction and conduction delay
Comparator
Medical therapy alone
Endpoint
Death from any cause or unplanned hospitalization for a major cardiovascular event
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis